SAN DIEGO, Dec. 14, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, engaged in the development of targeted cancer therapies, today announced the filing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback